200
Participants
Start Date
October 4, 2024
Primary Completion Date
October 4, 2026
Study Completion Date
October 4, 2026
Blood test: measurement of plasma antipsychotic concentration
Four blood tests are prospectively realized per patient during the study to measure the plasma concentration of antipsychotics (primary treatment: risperidone/paliperidone, olanzapine or aripiprazole). These blood samples are taken at the inclusion visit, at the follow-up visits 2 and 4 months after the inclusion visit, then at the end-of-study visit 6 months after the inclusion visit.
Voice interviews and questionnaires carried out via the CALLYOPE application
"Voice interviews carried out via the Callyope application: they consist of a series of tests, divided into two parts: Structured tasks (same content for each participant) and Semi-structured tasks (content varies for each participant).~The simultaneous analysis of several speech tasks allows us to break down the different stages of speech production and the important factors that influence its achievement.~In addition, patients will complete self-questionnaires via the application. Finally, lifestyle habits (sleep duration and number of steps) will be recorded via the application.~These different tests will be carried out on the application at the inclusion visit (M0), then every month (M1, M2, M3, M4, M5) until the end of study visit (M6)."
RECRUITING
Groupe Hospitalo-Universitaire Paris Psychiatrie et Neurosciences, Paris, Paris
NOT_YET_RECRUITING
Groupe Hospitalo-Universitaire Paris Psychiatrie & Neurosciences, Paris
Centre Hospitalier St Anne
OTHER